Acknowledgements
E.R.B.'s research was supported in part by a National Institutes of Health (NIH) grant NIANIH/R01AG043560 to the National Bureau of Economic Research (NBER). Views expressed in this article are those of the authors, and are not necessarily those of the NIH or the NBER.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.H.C is an employee and shareholder of Bristol-Myers Squibb. M.T. is President of Co-Bio Consulting L.L.C., which provides management consulting services to biomedical firms.
Supplementary information
Supplementary information S1 (box)
Data sources and categorization for biopharmaceutical company IPOs: 2010–2014 (PDF 377 kb)
Supplementary information S2 (box)
Investment model (PDF 531 kb)
Supplementary information
Supplementary information S3 (table) (XLSX 101 kb)
Supplementary information S4 (box)
Discussion of factors that potentially underpin the paradoxical findings (PDF 220 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Carter, P., Berndt, E., DiMasi, J. et al. Investigating investment in biopharmaceutical R&D. Nat Rev Drug Discov 15, 673–674 (2016). https://doi.org/10.1038/nrd.2016.104
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.104
- Springer Nature Limited
This article is cited by
-
Therapeutic Potentials and Candidates for COVID-19
Iranian Journal of Science (2023)